New progress in the diagnosis and treatment of hepatocellular carcinoma: a decade of grinding sword
10.3760/cma.j.cn501113-20210205-00069
- VernacularTitle:十年磨一剑：肝细胞癌诊疗新进展
- Author:
Hongyan LIU
1
;
Kunyuan WANG
;
Rong FAN
;
Jinlin HOU
Author Information
1. 南方医科大学南方医院感染内科肝病中心，广州 510515
- Keywords:
Hepatocellular carcinoma;
Surveillance;
Early diagnosis;
Multi-disciplinary team;
Systemic treatment
- From:
Chinese Journal of Hepatology
2021;29(2):111-115
- CountryChina
- Language:Chinese
-
Abstract:
Globally, hepatocellular carcinoma (HCC) is one of the most highly morbid, fatal, and malignant tumors, with a poor prognosis in advanced stage. In the past decade, new advances have been emerged in the field of HCC therapy, including surgery, ablation, transvascular intervention, external radiotherapy, and systemic therapy. Among them, systemic treatments, particularly targeted and immune checkpoint drugs have made outstanding progress, significantly improving the five-year survival rate of liver cancer patients. In addition, the management of liver cancer patients, especially the screening management and multidisciplinary collaborative diagnosis and treatment of high-risk populations, has significantly increased the early diagnosis rate and improved the overall treatment efficacy. Considering our country's condition and the development of existing treatment, the most effective strategy to reduce HCC mortality in the future is to accurately identify high-risk populations, increase the early diagnosis rate, and formulate personalized treatment strategies.
